Definium Therapeutics (NASDAQ:DFTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Definium Therapeutics (NASDAQ:DFTX – Free Report) from a sell rating to a hold rating in a report issued on Saturday,Wall Street Zen reports.

DFTX has been the subject of several other reports. Bank of America began coverage on shares of Definium Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $75.00 target price for the company. Robert W. Baird boosted their price target on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 15th. UBS Group restated a “buy” rating and issued a $70.00 price target on shares of Definium Therapeutics in a research note on Tuesday, September 15th. Canaccord Genuity Group set a $78.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $75.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $66.24.

Check Out Our Latest Analysis on DFTX

Definium Therapeutics Trading Down 6.0%

NASDAQ:DFTX opened at $30.16 on Friday. Definium Therapeutics has a one year low of $10.46 and a one year high of $49.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 15.53 and a quick ratio of 6.95. The company’s 50-day simple moving average is $35.91 and its 200 day simple moving average is $30.45. The firm has a market capitalization of $4.05 billion, a P/E ratio of -9.70 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.09. As a group, analysts forecast that Definium Therapeutics will post -2.94 EPS for the current fiscal year.

Insider Activity

In other Definium Therapeutics news, insider Matthew T. Wiley sold 3,097 shares of the firm’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $113,257.29. Following the completion of the sale, the insider directly owned 359,036 shares in the company, valued at approximately $13,129,946.52. This trade represents a 0.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the firm’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $123,496.89. Following the sale, the chief financial officer owned 394,528 shares of the company’s stock, valued at approximately $14,427,888.96. This represents a 0.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 71,098 shares of company stock worth $2,626,115. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP bought a new stake in shares of Definium Therapeutics in the second quarter worth approximately $138,755,000. Russell Investments Group Ltd. raised its holdings in shares of Definium Therapeutics by 116.1% during the third quarter. Russell Investments Group Ltd. now owns 331,702 shares of the company’s stock valued at $12,647,000 after purchasing an additional 178,225 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Definium Therapeutics during the second quarter valued at approximately $6,992,000. Goldman Sachs Group Inc. lifted its position in Definium Therapeutics by 7.5% during the third quarter. Goldman Sachs Group Inc. now owns 1,935,743 shares of the company’s stock valued at $73,674,000 after purchasing an additional 134,891 shares during the period. Finally, Moody Aldrich Partners LLC lifted its position in Definium Therapeutics by 191.8% during the third quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock valued at $5,666,000 after purchasing an additional 97,845 shares during the period. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

(Get Free Report)

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.

Further Reading

Analyst Recommendations for Definium Therapeutics (NASDAQ:DFTX)

Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.